Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy.
Tokita
K
K
Maki
K
K
Tadokoro
J
J
Nakamura
Y
Y
Arai
Y
Y
Sasaki
K
K
Eguchi-Ishimae
M
M
Eguchi
M
M
Mitani
K
K
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D002881:Chromosomes, Human, Pair 12; D002895:Chromosomes, Human, Pair 5; D002908:Chronic Disease; D017809:Fatal Outcome; D006801:Humans; D000068877:Imatinib Mesylate; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics*; D008297:Male; D015514:Oncogene Proteins, Fusion / Q000096:biosynthesis / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use*; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*; D014158:Transcription, Genetic; D014178:Translocation, Genetic
D001549:Benzamides; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; C120888:TEL-PDGFRbeta fusion protein, human; D000068877:Imatinib Mesylate